3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
16
Ovarian Neoplasms
9
Breast Neoplasms
9
Fallopian Tube Neoplasms
5
Carcinoma, Ovarian Epithelial
5
Squamous Cell Carcinoma of Head and Neck
4
Triple Negative Breast Neoplasms
3
Neoplasm Metastasis
3
Lung Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Endometrial Neoplasms
3
Carcinoma
3
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Non Small Cell Lung Carcinoma NSCLC
2
Neoplasms, Unknown Primary
2
Neoplasms
2
NSCLC
2
Melanoma
2
Esophageal Neoplasms
2
Adenocarcinoma
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Unresectable Stage III NSCLC
1
Triple Negative Metastatic Breast Cancer
1
Thyroid Neoplasms
1
Thrombocytopenia
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Interventions
Fluorouracil
67
Radiotherapy
53
Cisplatin
52
Oxaliplatin
47
Leucovorin
37
Paclitaxel
36
Irinotecan
27
Docetaxel
23
Capecitabine
20
Nivolumab
16
Carboplatin
16
pembrolizumab
15
Radiation
15
Neoadjuvant Therapy
15
Surgical Procedures, Operative
12
Cetuximab
12
durvalumab
9
Taxes
8
Folfox protocol
8
Drug Therapy
8
Chemotherapy, Adjuvant
8
Trastuzumab
7
Magnetic Resonance Spectroscopy
7
Gefitinib
7
tremelimumab
6
Endoscopy, Digestive System
6
Endoscopy
6
Biopsy
6
Specimen Handling
5
Ramucirumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Adenocarcinoma Of Esophagus
×
CP protocol
×
Clear all
NCT01404156
2024-08-28
POWERRANGER
CancerCare Manitoba
Phase 2/3
Completed
29 enrolled